Genetic Technologies Limited (NASDAQ: GENE) started the day on April 09, 2021, with a price increase of 6.53% at $4.57. During the day, the stock rose to $5.74 and sunk to $4.2301 before settling in for the price of $4.29 at the close. Taking a more long-term approach, GENE posted a 52-week range of $1.55-$10.30.
Meanwhile, its Annual Earning per share during the time was 29.10%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -157.90%. This publicly-traded company’s shares outstanding now amounts to $15.03 million, simultaneously with a float of $14.90 million. The organization now has a market capitalization sitting at $68.69 million. At the time of writing, stock’s 50-day Moving Average stood at $4.56, while the 200-day Moving Average is $3.80.
It is quite fundamental to gauge the extent of the productivity of the business which is accounted for 64 workers. For the Profitability, stocks gross margin was -4485.32, operating margin was -75173.12 and Pretax Margin of -69433.60.
Genetic Technologies Limited (GENE) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Diagnostics & Research Industry. Genetic Technologies Limited’s current insider ownership accounts for 86.50%, in contrast to 1.90% institutional ownership.
Genetic Technologies Limited (GENE) Earnings and Revenue Records
This company achieved a net margin of -61830.19 while generating a return on equity of -82.49. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Genetic Technologies Limited’s EPS decrease for this current 12-month fiscal period is -157.90%.
Genetic Technologies Limited (NASDAQ: GENE) Trading Performance Indicators
Let’s observe the current performance indicators for Genetic Technologies Limited (GENE). It’s Quick Ratio in the last reported quarter now stands at 14.50. The Stock has managed to achieve an average true range (ATR) of 0.42. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2671.19.
In the same vein, GENE’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.68.
Technical Analysis of Genetic Technologies Limited (GENE)
If we take a close look at the recent performances of Genetic Technologies Limited (NASDAQ: GENE), its last 5-days Average volume was 5.14 million that shows progress from its year to date volume of 2.07 million. During the previous 9 days, stock’s Stochastic %D was recorded 56.99% While, its Average True Range was 0.44.
Raw Stochastic average of Genetic Technologies Limited (GENE) in the period of the previous 100 days is set at 31.63%, which indicates a major fall in contrast to 38.10% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 65.63% that was lower than 106.99% volatility it exhibited in the past 100-days period.